DongKook Life Science
동국생명과학 · 303810
Health Care Pharmaceuticals · KOSDAQ
Market cap US$66.4M (₩91.6B)
Overview
DongKook Life Science makes contrast agents, injectable medicines that make organs, blood vessels, and tissue show up clearly on medical scans such as X-ray, CT, and MRI, supplied exclusively to hospitals as prescription-only drugs.
Its products span iodine-based agents for X-ray and CT imaging, gadolinium-based agents for MRI, and iodised-oil agents used in interventional radiology procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business is contrast agents, which it complements with a separate division that imports, distributes, and manufactures diagnostic imaging equipment and medical devices. It supplies partners across roughly two dozen countries worldwide.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2024US$95.5M
- FY2025US$94.5M
Operating profit
- FY2024US$8.6M
- FY2025US$9.5M
Net income
- FY2024US$1.6M
- FY2025US$6.3M
Key ratios (FY2025)
Why it matters
The company distributes its contrast agents through a network of partners spanning over two dozen countries, giving it an international commercial footprint unusual for a KOSDAQ-listed specialist pharmaceutical firm.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?